Inhibitory Mechanism of the CXCR4 Antagonist T22 against Human Immunodeficiency Virus Type 1 Infection

ABSTRACT We recently reported that a cationic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), specifically inhibits human immunodeficiency virus type 1 (HIV-1) infection mediated by CXCR4 (T. Murakami et al., J. Exp. Med. 186:1389–1393, 1997). Here we demonstrate that T22 effectively inhibits replication of T-tropic HIV-1, including primary isolates, but not of non-T-tropic strains. By using a panel of chimeric viruses between T- and M-tropic HIV-1 strains, viral determinants for T22 susceptibility were mapped to the V3 loop region of gp120. T22 bound to CXCR4 and interfered with stromal-cell-derived factor-1α–CXCR4 interactions in a competitive manner. Blocking of anti-CXCR4 monoclonal antibodies by T22 suggested that the peptide interacts with the N terminus and two of the extracellular loops of CXCR4. Furthermore, the inhibition of cell-cell fusion in cells expressing CXCR4/CXCR2 chimeric receptors suggested that determinants for sensitivity of CXCR4 to T22 include the three extracellular loops of the coreceptor.

[1]  M. Baba,et al.  T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure , 1999, Journal of Virology.

[2]  O. Yoshie,et al.  T-Tropic Human Immunodeficiency Virus Type 1 (HIV-1)-Derived V3 Loop Peptides Directly Bind to CXCR-4 and Inhibit T-Tropic HIV-1 Infection , 1998, Journal of Virology.

[3]  R. Doms,et al.  CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. , 1998, Journal of reproductive immunology.

[4]  R. Doms,et al.  An Orphan Seven-Transmembrane Domain Receptor Expressed Widely in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus , 1998, Journal of Virology.

[5]  R. Doms,et al.  HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  E. De Clercq,et al.  Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100 , 1998, Journal of Virology.

[7]  Miriam K. Konkel,et al.  The Orphan Seven-Transmembrane Receptor Apj Supports the Entry of Primary T-Cell-Line-Tropic and Dualtropic Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[8]  A. Otaka,et al.  Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. , 1998, Bioorganic & medicinal chemistry.

[9]  Ying Sun,et al.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. , 1998, Science.

[10]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[11]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[12]  Zi-Xuan Wang,et al.  CXCR4 Sequences Involved in Coreceptor Determination of Human Immunodeficiency Virus Type-1 Tropism , 1998, The Journal of Biological Chemistry.

[13]  M. Kannagi,et al.  Human T-cell leukemia virus type 1 Tax protein induces the expression of lymphocyte chemoattractant SDF-1/PBSF. , 1998, Virology.

[14]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[15]  S. Nisole,et al.  Spontaneous Mutations in the env Gene of the Human Immunodeficiency Virus Type 1 NDK Isolate Are Associated with a CD4-Independent Entry Phenotype , 1998, Journal of Virology.

[16]  R. Doms,et al.  Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses , 1997, Journal of virology.

[17]  J. Kira,et al.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo , 1997, Journal of virology.

[18]  R. Doms,et al.  A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor , 1997, The Journal of experimental medicine.

[19]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[20]  N. Yoshida,et al.  A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection , 1997, The Journal of experimental medicine.

[21]  R. Doms,et al.  Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. , 1997, Virology.

[22]  Y. Kirino,et al.  Membrane permeabilization mechanisms of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog. , 1997, Biochemistry.

[23]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[24]  D. Littman,et al.  Expression cloning of new receptors used by simian and human immunodeficiency viruses , 1997, Nature.

[25]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[26]  N. Heveker,et al.  Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. , 1997, Science.

[27]  R. Doms,et al.  Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Peden,et al.  STRL33, A Novel Chemokine Receptor–like Protein, Functions as a Fusion Cofactor for Both Macrophage-tropic and T Cell Line–tropic HIV-1 , 1997, The Journal of experimental medicine.

[29]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[30]  R. Doms,et al.  CD4-Independent Infection by HIV-2 Is Mediated by Fusin/CXCR4 , 1996, Cell.

[31]  Joseph Sodroski,et al.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5 , 1996, Nature.

[32]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[33]  A. Garzino-Demo,et al.  The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection , 1996, Nature Medicine.

[34]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[35]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[36]  J. Sodroski,et al.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.

[37]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[38]  Marc Parmentier,et al.  A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.

[39]  Ying Sun,et al.  The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.

[40]  Virginia Litwin,et al.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.

[41]  Stephen C. Peiper,et al.  Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.

[42]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[43]  E. Bradbury,et al.  Structure and Polymorphism of HIV-1 Third Variable Loops (*) , 1996, The Journal of Biological Chemistry.

[44]  E. De Clercq,et al.  The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication , 1996, Journal of virology.

[45]  K. Boulez,et al.  Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions. , 1996, European journal of biochemistry.

[46]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[47]  K. Boulez,et al.  The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV‐1 shows pronounced helical character in solution , 1995, FEBS letters.

[48]  E. Bradbury,et al.  Local and Global Structural Properties of the HIV-MN V3 Loop (*) , 1995, The Journal of Biological Chemistry.

[49]  A. Otaka,et al.  Solution-phase synthesis of an anti-human immunodeficiency virus peptide, T22 ([Tyr5,12,Lys7]-polyphemusin II), and the modification of Trp by the p-methoxybenzyl group of Cys during trimethylsilyl trifluoromethanesulfonate deprotection. , 1995, Chemical & pharmaceutical bulletin.

[50]  A. Otaka,et al.  Structure-activity relationships of an anti-HIV peptide, T22. , 1994, Biochemical and biophysical research communications.

[51]  Y. Koyanagi,et al.  Cell type-specific heterogeneity of the HIV-1 V3 loop in infected individuals: selection of virus in macrophages and plasma. , 1994, Virology.

[52]  H. Kikutani,et al.  Molecular cloning and structure of a pre-B-cell growth-stimulating factor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. Honjo,et al.  Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. , 1993, Science.

[54]  H. Tamamura,et al.  Antimicrobial activity and conformation of tachyplesin I and its analogs. , 1993, Chemical & pharmaceutical bulletin.

[55]  D. Kohda,et al.  A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance. , 1993, Biochimica et biophysica acta.

[56]  T Ueda,et al.  A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II). , 1992, Biochemical and biophysical research communications.

[57]  N. Fujii,et al.  Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion , 1992, Antimicrobial Agents and Chemotherapy.

[58]  E. Hunter,et al.  V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. , 1992, Virology.

[59]  S. M. Stearns,et al.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity , 1992, Journal of virology.

[60]  C. Cheng‐Mayer,et al.  Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 , 1991, Journal of virology.

[61]  B. Chesebro,et al.  Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages , 1991, Journal of virology.

[62]  D. Dimitrov,et al.  Initial stages of HIV-1 envelope glycoprotein-mediated cell fusion monitored by a new assay based on redistribution of fluorescent dyes. , 1991, AIDS research and human retroviruses.

[63]  N. Fujii,et al.  Interactions of an antimicrobial peptide, tachyplesin I, with lipid membranes. , 1991, Biochimica et biophysica acta.

[64]  C. Cheng‐Mayer,et al.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp!20 gene , 1991, Nature.

[65]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[66]  H. Vinters,et al.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.

[67]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[68]  H. Yoshiyama,et al.  Narrow host range of AIDS-related retroviruses (YU-1, 2, 3, 4) isolated from Japanese hemophiliacs: inability to infect H9, Molt-4, and MT-4 cells. , 1986, Japanese journal of cancer research : Gann.

[69]  J. Moore,et al.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.

[70]  A. Otaka,et al.  Unambiguous synthesis of stromal cell-derived factor-1 by regioselective disulfide bond formation using a DMSO–aqueous HCl system , 1998 .